SummaryThis study will run in three stages: dose escalation, dose exploration and dose expansion.
In Part A (dose escalation), participants will receive tuspetinib daily. Dose escalation cohort is planned for up to 6 cohort levels.
In Part B (dose exploration), participants will receive tuspetinib daily. Dose exploration is planned for up to 4 dose levels.
Part C (dose expansion) consists of two treatment arms and participants and participants will be randomly assigned to either arm. Participants in Arm 1 will receive tuspetinib alone, daily. Participants in Arm 2 will receive tuspetinib plus venetoclax (another targeted therapy).
Use the hyperlinks, where available to access additional clinical trial information.
Aptose Biosciences Inc.
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)